August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Guillermo De Velasco: Meet the Experts of VIRO 2025
Aug 26, 2025, 13:50

Guillermo De Velasco: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

  • The congress is free to attend.
  • Register via the link.

Co-Chair of VIRO

ImagesName
Rana McKay -OncoDaily

Rana McKay

Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
 “Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Guillermo De Velasco

Dr. Guillermo de Velasco serves as the Head of Pneumology and Oncology at the Urological Hospital Humanitas Gavazzeni Section in Madrid, Spain. He is a distinguished expert specializing in variant histologies of renal cell carcinoma (RCC), with a particular focus on the challenging sarcomatoid RCC subtype.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. de Velasco will present on “Sarcomatoid RCC: Diagnosis and Treatment.” His session, part of the Variant Histologies in RCC track, will highlight:

  • Diagnostic criteria and the challenges unique to sarcomatoid RCC.
  • Current therapeutic landscapes alongside emerging treatment strategies targeting this aggressive RCC variant.
  • Biological insights into sarcomatoid RCC that influence treatment decisions and patient management.
  • Approaches to optimize patient outcomes and care for those with variant RCC histologies.

Dr. de Velasco applies a meticulous and targeted approach to the diagnosis and treatment of complex RCC subtypes, aiming to deliver personalized care that effectively addresses the unique challenges of these rare variants.

Global Voices in Renal Oncology (VIRO) 2025

Guillermo De Velasco